An observational study in STIs, sponsored by Shenzhen Maternity & Child Healthcare Hospital. Not yet recruiting at 43 sites in China. Open to female participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Shenzhen Maternity & Child Healthcare Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Sexually Transmitted Diseases with a site in China — 2 open to participants now, 2 under way, none of them phase 3. Sexually Transmitted Diseases · China.
Among the 11 studies in Sexually Transmitted Diseases with a site in China, this one is the only one that started in 2026, is one of 4 observational ones, and was the 11th registered.
525 studies on the registry are indexed under Sexually Transmitted Diseases; 79 are open to participants now.
Browse Sexually Transmitted Diseases studies →2 of the 11 studies in Sexually Transmitted Diseases with a site in China are open now. Recruiting first, the newest first:
National Research Institute for Family Planning, China · Sites in China
Ages 20–45 · Women only · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 49 Sexually Transmitted Diseases studies recruiting now, 30 (61%) set no upper age limit and 17 (35%) stop at 75 or younger; 23 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 60 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 7,574 is above the median of 578 across 93 observational studies indexed under Sexually Transmitted Diseases.
Median enrollment 1,200 across the 7 interventional studies, 5,650 across the 4 observational. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 11 have an industry lead sponsor. The 9 most frequent:
Shenzhen Maternity & Child Healthcare Hospital is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Shenzhen Maternity & Child Healthcare Hospital has 1 study filed under Sexually Transmitted Diseases — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Sexually Transmitted Diseases with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicenter, observational study is a 5-year longitudinal follow-up extending the CALM2004 cohort. It aims to enroll 7,574 women aged 18-60 to investigate the long-term impact of vaginal microbiome characteristics and sexually transmitted infections (STIs) on cervical lesion progression. By collecting vaginal secretions, and blood samples, the study will evaluate the 5-year cumulative incidence of CIN2+ and determine how specific microbial infections (e.g., Up6, MH) influence clinical outcomes, providing high-level evidence for cervical cancer prevention strategies.
A total of 7,574 women aged 18-60 years who previously participated in the baseline of the CALM2004 multicenter cohort study will be recruited for this 5-year longitudinal follow-up. This is a multicenter study, and participants will be recruited through targeted invitations from the research team members. The study population consists of women with a broad spectrum of baseline vaginal microecological statuses and varying risks of STIs and cervical lesions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A total of 7,574 women aged 18-60 who previously participated in the CALM2004 baseline study will be enrolled for a 5-year longitudinal follow-up. Participants will undergo comprehensive assessments including questionnaires, vaginal secretion collection for metagenomic sequencing, cervical exfoliated cells for TCT and STI nucleic acid testing, and venous blood testing. No specific interventions will be administered.
Cumulative incidence of CIN2+ at 5 years
The incidence rate of histologically confirmed Cervical Intraepithelial Neoplasia grade 2 or 3 (CIN2/3) or invasive cervical cancer occurring for the first time during the follow-up period, among participants who had no cervical lesions or were \<CIN2 at baseline
Time frame: 5 years
New incidence and progression rates of ASC-US+ cytological abnormalities
ASC-US+ new incidence: First occurrence of ASC-US or higher cytological abnormality during follow-up in participants with normal baseline cytology. ASC-US+ progression: First occurrence of LSIL/HSIL or higher cytological abnormality during follow-up in participants with baseline ASC-US. Cytology is evaluated according to the Bethesda System for Reporting Cervical Cytology.
Time frame: 5 years
HPV and STI incidence, clearance, and persistent/recurrent infection rates
HPV new infection: baseline negative, follow-up positive; HPV clearance: baseline positive, follow-up negative; HPV persistent infection: same genotype positive at both baseline and follow-up. STI new infection: baseline negative, follow-up positive; STI clearance: baseline positive, follow-up same genotype negative; STI recurrent infection: same genotype positive at both baseline and follow-up.
Time frame: 5 years
Start is estimated for Dec 2026; primary completion for Jun 2028, 18 months later.
Of 42 non-industry observational studies under Sexually Transmitted Diseases, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 57. This study's planned 18 months is below that.
Counting every sponsor, half of 48 studies reached it within 26 months; a quarter within 15 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sexually Transmitted Diseases →
Shenzhen Maternity & Child Healthcare Hospital